Celleron Therapeutics is a biopharmaceutical company focusing on new and innovative cancer treatments.

Celleron’s Vision is to build a global pipeline of clinical products which are safe and effective in unmet indications, supported by a precision medicine platform.

It has two registrational study assets, zabinostat and emactuzumab, which offer near term revenues. It is also in active discussion with major multinational pharmaceutical companies to acquire new assets for clinical development and commercialisation.